

BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 23840

Title: Sacral Neuromodulation for Fecal Incontinence: Adverse Events Registered by the

Federal Drug Administration Reviewer's code: 00040529 Reviewer's country: Italy Science editor: Ya-Juan Ma

Date sent for review: 2015-12-22 10:27

Date reviewed: 2016-01-02 00:49

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[] Grade A: Excellent	[] Grade A: Priority publishing	Google Search:	[] Accept
[] Grade B: Very good	[Y] Grade B: Minor language	[] The same title	[] High priority for
[] Grade C: Good	polishing	[] Duplicate publication	publication
[Y] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y]No	[] Minor revision
	[] Grade D: Rejected	BPG Search:	[Y] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y]No	

COMMENTS TO AUTHORS

This is a systematic review on the Adverse Event by FDA after SNS for FI. The paper is overall well written, with tables and figures helping in the assessment of results. An advice to the authors is to structure Table 1 including in the first column the name of the first author of the study. In Figures 1-2, the names of the first author should replace the name of the journals. My major concern on this review is the confusion or miss-understanding regarding the terminology "ADVERSE EVENTS". In my opinion, authors should limit their review and analysis of the results to the complications due to the device (infection, pain, pocket erosion) that may need re-intervention. Lack of benefit, not strictly related to complications after placement of the device, should not be considered adverse event. Programming problems are not adverse event, but part of the treatment. As well lack of benefit with time, are not adverse event, but should be considered as long-term outcome or results. We strongly recommend the authors to limit or to focus their review to the "TRUE" adverse events, in order to avoid the wrong message that SNS is related to a HIGH RATE of complications.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 23840

Title: Sacral Neuromodulation for Fecal Incontinence: Adverse Events Registered by the

Federal Drug Administration Reviewer's code: 00042186 Reviewer's country: Italy Science editor: Ya-Juan Ma

Date sent for review: 2015-12-22 10:27

Date reviewed: 2016-01-07 16:28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[] Accept
[Y] Grade B: Very good	[] Grade B: Minor language	[] The same title	[] High priority for
[] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y]No	[Y] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y]No	

COMMENTS TO AUTHORS

This is a very well conducted sistematic review on adverse events in sacral neuromodulation. The only but very important flaw is that authors consider reprogramming sessions and replacement of depleted neurostimulator as adverse events. These events belong to the natural history of this therapy and they must not be compared to infective or painful complications. This is the reason because complications' and reoperative rate is so high and it could lead to wrong and inaccurate final conclusions. I recommend authors to separe data regarding real complications from normal "maintenance" events in the selected series (if possible) to achieve actual and effective conclusions.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 23840

Title: Sacral Neuromodulation for Fecal Incontinence: Adverse Events Registered by the

Federal Drug Administration Reviewer's code: 00068989 Reviewer's country: Israel Science editor: Ya-Juan Ma

Date sent for review: 2015-12-22 10:27

Date reviewed: 2016-01-23 18:15

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[] Grade A: Priority publishing	Google Search:	[] Accept
[] Grade B: Very good	[Y] Grade B: Minor language	[] The same title	[] High priority for
[] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y]No	[Y] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Well written systematic review few changes should be made- especially regarding what is true adverse event and what is the natural history of SNS